急性白血病患者骨髓细胞中TSLC1的表达及其临床意义

Expression of tumor suppressor in lung cancer 1 in the bone marrow cells of patients with acute leukemia and its clinical significance

目的：观察肺癌肿瘤抑制物1（tumor suppressor in lung cancer 1,TSLC1）在急性白血病（acute leukemia,AL）患者骨髓细胞中的表达情况,探讨其在AL的早期诊断、预后评估及指导治疗中的意义。方法：应用半定量逆转录-聚合酶链反应检测39例AL患者及10例对照组骨髓细胞中TSLC1 mRNA的表达情况。结果：对照组TSLC1表达阳性率为80.00%,AL组为12.82%,两组差异有统计学意义（P〈0.01）。急性髓细胞白血病（acute myeloid leukemia,AML）中M1、M2及M5型与对照组TSLC1表达差异均有统计学意义（P〈0.05-P〈0.01）;M3、M4型与对照组TSLC1表达差异均无统计学意义（P〉0.05）,各亚型间比较差异均无统计学意义（P〉0.05）。结论：AL中TSLC1失表达是一个频发事件,可能与AL的发生、发展有关,对AL的早期诊断、预后评估及指导治疗具有重要意义。

Objective：To determine the expression of tumor suppressor in lung cancer 1 （TSLC1） in the bone marrow cells （BMC） of patients with acute leukemia （ AL）, and to evaluate its significance in early diagnosis, prognosis and treatment of AL. Methods ： Expression of TSLC1 mRNA in the BMC of 39 AL patients and 10 normal subjects was determined by semi-quantitative reverse transcription polymerase chain reaction （RT-PCR）. Results：The positive expression of TSLC1 was 80.00 % in the control group, while it was 12.82% in the AL group. The difference was significant （ P 〈 0.01 ）. The difference of M1, M2 and M5 in the acute myeloid leukemia （AML） group and the TSLC1 in the control group had statistical significance （P 〈 0.05 -P 〈 0.01 ） ;the difference of M3 and M4 in AML group and the expression of TSLC1 in the control group showed no statistical significance （ P 〉 0.05 ） ; the subtype comparison was not statistically different （P 〉 0.05 ）. Conclusions：The loss expression of TSLC1 in AL is a frequent event, which is likely to be correlated with the genesis and progress of AL,and may be of great value in the early diagnosis,prognosis and treatment of AL.